NIKKEI 225
38,266.30 -7.75 (-0.02%) HANG SENG
18,178.99 +415.96 (+2.34%) CRUDE OIL
79.47 +0.47 (+0.59%) GOLD FUTURES
2,324.30 +13.30 (+0.58%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,797.58 -2,041.51 (-4.27%)
ALX Oncology Holdings Inc. (ALXO)
After hours:
| Previous close | 17.02 |
| Open | 17.02 |
| Bid | 16.85 x 100 |
| Ask | 16.97 x 300 |
| Day's range | 16.88 - 17.47 |
| 52-week range | 3.94 - 17.47 |
| Volume | |
| Avg. volume | 494,832 |
| Market cap | 855.45M |
| Beta (5Y monthly) | 1.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.74 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.15 |
GlobeNewswireALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the initiation of a Phase 2 investigator-sponsored trial (“IST”) of neoadjuvant radiation and evorpacept, a next-generation CD47 blocker, in combination KEYTRUDA® (pembrolizumab) in patients with previously untreated and early-stage locally advanc
- GlobeNewswire
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the American Society of Cancer Oncology (“ASCO”), which will be held in Chicago from May 31-June 4, 2024. Session titles and information for the two abstracts are listed below and are now
ZacksRoche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
